What do systematic reviews say?

Probiotic + 5‐aminosalicylic acid (5‐ASA) (mesalazine) vs 5‐aminosalicylic acid (5‐ASA) (mesalazine)

The review found no eligible studies for this question.

• Probiotics for maintenance of remission in ulcerative colitis 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Chemotherapy vs chemotherapy alone

• Salvage systemic therapy for advanced gastric and oesophago‐gastric junction adenocarcinoma 2020 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 70 participants
  Very low

Biological therapy vs placebo, best supportive care (BSC) or no treatment

• Salvage systemic therapy for advanced gastric and oesophago‐gastric junction adenocarcinoma 2020 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 283 participants
  Low

Chemmotherapy combined with biological therapy vs chemotherapy alone

Chemmotherapy combined with biological therapy showed no clear difference in quality of life (QoL) compared with chemotherapy (low certainty).

• Salvage systemic therapy for advanced gastric and oesophago‐gastric junction adenocarcinoma 2020 · Cochrane Headline outcomes only
  HR 0.88 [0.74, 1.04]
  2 studies · 1154 participants
  Low

Summary of findings table (subcomparison 1): chemotherapy or targeted therapy plus best supportive care (BSC) vs BSC

• Palliative chemotherapy and targeted therapies for esophageal and gastroesophageal junction cancer 2017 · Cochrane Headline outcomes only
  no estimate extracted
  4 studies · 1129 participants
  Very low

Summary of findings table (subcomparison 2): second‐line chemotherapy or targeted therapy agent(s) plus control intervention vs control intervention

• Palliative chemotherapy and targeted therapies for esophageal and gastroesophageal junction cancer 2017 · Cochrane Headline outcomes only
  no estimate extracted
  4 studies · 1638 participants
  Very low

Summary of findings table (subcomparison 3): chemotherapy agent(s) plus control intervention vs control intervention

• Palliative chemotherapy and targeted therapies for esophageal and gastroesophageal junction cancer 2017 · Cochrane Headline outcomes only
  no estimate extracted
  450 participants
  Very low

Summary of findings table (subcomparison 4): targeted therapy agent plus control intervention vs control intervention

• Palliative chemotherapy and targeted therapies for esophageal and gastroesophageal junction cancer 2017 · Cochrane Headline outcomes only
  no estimate extracted
  4 studies · 2054 participants
  Very low

Summary of findings table (subcomparison 5): chemotherapy or targeted therapy agent(s) plus control intervention vs control intervention

• Palliative chemotherapy and targeted therapies for esophageal and gastroesophageal junction cancer 2017 · Cochrane Headline outcomes only
  no estimate extracted
  5 studies · 1870 participants
  Very low

Probiotics vs 5‐aminosalicylic acid (5‐ASA) (mesalazine)

• Probiotics for maintenance of remission in ulcerative colitis 2020 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 222 participants
  Low

5‐ASA vs placebo

The review found no eligible studies for this question.

• Oral 5‐aminosalicylic acid for maintenance of surgically‐induced remission in Crohn's disease 2019 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

High dose 5‐ASA vs low dose 5‐ASA

The review found no eligible studies for this question.

• Oral 5‐aminosalicylic acid for maintenance of surgically‐induced remission in Crohn's disease 2019 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

5‐ASA vs purine antimetabolites

It is very uncertain whether 5‐ASA changes health related quality of life compared with purine antimetabolites (very low certainty).

• Oral 5‐aminosalicylic acid for maintenance of surgically‐induced remission in Crohn's disease 2019 · Cochrane Headline outcomes only
  RR 1.42 [0.27, 7.46]
  1 study · 35 participants
  Very low

5‐ASA vs anti TNF‐ɑ

It is very uncertain whether 5‐ASAs changes health related quality of life compared with anti TNF‐ɑ (very low certainty).

• Oral 5‐aminosalicylic acid for maintenance of surgically‐induced remission in Crohn's disease 2019 · Cochrane Headline outcomes only
  RR 0.19 [0.07, 0.54]
  1 study · 34 participants
  Very low

5‐ASA vs no treatment

The review found no eligible studies for this question.

• Oral 5‐aminosalicylic acid for maintenance of surgically‐induced remission in Crohn's disease 2019 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Sulphasalazine vs placebo

The review found no eligible studies for this question.

• Oral 5‐aminosalicylic acid for maintenance of surgically‐induced remission in Crohn's disease 2019 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found